- Home
- JANX vs SPRY Comparison
JANX vs SPRY Comparison
Compare JANX & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- SPRY
- Stock Information
- Founded
- JANX 2017
- SPRY 2015
- Country
- JANX United States
- SPRY United States
- Employees
- JANX N/A
- SPRY N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- JANX Health Care
- SPRY Health Care
- Exchange
- JANX Nasdaq
- SPRY Nasdaq
- Market Cap
- JANX 1.5B
- SPRY 1.8B
- IPO Year
- JANX 2021
- SPRY N/A
- Fundamental
- Price
- JANX $25.96
- SPRY $17.87
- Analyst Decision
- JANX Strong Buy
- SPRY Strong Buy
- Analyst Count
- JANX 8
- SPRY 4
- Target Price
- JANX $90.63
- SPRY $28.75
- AVG Volume (30 Days)
- JANX 839.1K
- SPRY 1.5M
- Earning Date
- JANX 08-06-2025
- SPRY 08-05-2025
- Dividend Yield
- JANX N/A
- SPRY N/A
- EPS Growth
- JANX N/A
- SPRY N/A
- EPS
- JANX N/A
- SPRY N/A
- Revenue
- JANX $9,336,000.00
- SPRY $97,122,000.00
- Revenue This Year
- JANX N/A
- SPRY N/A
- Revenue Next Year
- JANX $1,470.82
- SPRY $170.64
- P/E Ratio
- JANX N/A
- SPRY N/A
- Revenue Growth
- JANX 28.12
- SPRY 971120.00
- 52 Week Low
- JANX $22.48
- SPRY $8.91
- 52 Week High
- JANX $71.71
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- JANX 53.36
- SPRY 57.82
- Support Level
- JANX $25.81
- SPRY $17.43
- Resistance Level
- JANX $27.31
- SPRY $18.17
- Average True Range (ATR)
- JANX 1.30
- SPRY 0.69
- MACD
- JANX 0.08
- SPRY -0.09
- Stochastic Oscillator
- JANX 45.02
- SPRY 66.52
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.